Why

Currently, managing T1D is relentless. It requires people to constantly balance insulin delivery against the amount of food eaten, the amount of exercise, and even the stress of the workplace or school. Few people, regardless of age, can focus on this balancing act every moment of the day. But technology can.


What

Artificial pancreas (AP) systems will be the most revolutionary advance in diabetes care since the discovery of insulin. Like the body’s pancreas, AP systems will react to rising blood-glucose levels by combining monitoring technology with insulin pumps to provide the right amount of insulin at the right time. Not only will AP systems result in much tighter control, lowering the risk of health complications later in life, they will also reduce the constant worry about blood-sugar levels and what must be done to manage them.


How

Back in 2006, JDRF launched the Artificial Pancreas Project. The goal of the project was simple but stunningly ambitious: use new technology and science to replicate, as closely as possible, the operation of a normal human pancreas.

When JDRF stepped in, little was happening in the field. But through a strategic approach of direct funding and collaborative ventures, dramatic advances using integrated smart technology to automate insulin management have already occurred—with more in development and being applied to real-world solutions.

Today, we’re drawing closer to seeing AP systems come to market and closer to our end goal of Type None. In late 2012, the FDA released final guidance for device makers to secure approval and commercialize the system. Outpatient trials of first-generation systems are already under way. You can see one person’s experience living with an AP system.

But as game changing as the initial AP systems will be, they’re only one milestone in our sights. And we need your support to further the advancements. It’s going to take tens of millions of dollars for JDRF to continue working on initiatives to advance AP systems, such as developing even faster-acting insulin and delivery to boost the overall performance of the AP system; improving blood-glucose sensing technology to achieve greater accuracy, ease of use, and more accurate control; and creating systems that add hormones such as amylin, glucagon, or leptin to allow for full automation and the most precise control imaginable.

All of these initiatives are bringing us closer to making an artificial pancreas that fully automates insulin dosing and achieving our ultimate goal of turning Type One into Type None.

Help turn Type One into Type None.

Availability for T1Ds:
Short term, extending into mid term with growing numbers participating in human testing.
Current Need:
$50 million
Anticipated 5-year need:
$85 million

Every dollar will help bring us closer to a world without T1D. Please consider a donation today.

Donate Now

Learn more

Want to know more about the artificial pancreas and get updates about this life-changing therapy? Download our white paper and stay informed.

White Paper